symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
OCS,10.28,0.141645,16862,374555912,0,6.26-14.5,-0.71,Oculis Holding AG,USD,0001953530,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://oculis.com,"Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.","Dr. Riad  Sherif M.B.A., M.D.",Healthcare,CH,28,41 58 810 0182,Bahnhofstrasse 7,Zug,,6300,,0,https://financialmodelingprep.com/image-stock/OCS.png,2021-05-18,True,False,True,False,False
